Array
(
 [Ovarian Cancer] => Array
 (
 [Austin] => https://www.survivornet.com/austin/
 [Baltimore] => https://www.survivornet.com/baltimore/
 [Charlotte] => https://www.survivornet.com/charlotte/
 [Cleveland] => https://www.survivornet.com/cleveland/
 [Columbus] => https://www.survivornet.com/columbus/
 [Dallas / Ft. Worth] => https://www.survivornet.com/dallas-ftworth/
 [Denver] => https://www.survivornet.com/denver/
 [Detroit] => https://www.survivornet.com/detroit/
 [Indianapolis] => https://www.survivornet.com/indianapolis-ovarian-cancer/
 [Louisville] => https://www.survivornet.com/louisville/
 [Memphis] => https://www.survivornet.com/memphis/
 [Minneapolis] => https://www.survivornet.com/minneapolis/
 [Nashville] => https://www.survivornet.com/nashville/
 [Phoenix] => https://www.survivornet.com/phoenix/
 [Portland] => https://www.survivornet.com/portland/
 [Salt Lake City] => https://www.survivornet.com/salt-lake-city/
 [San Antonio] => https://www.survivornet.com/san-antonio/
 [San Diego] => https://www.survivornet.com/san-diego/
 [San Francisco] => https://www.survivornet.com/san-francisco/
 [San Jose] => https://www.survivornet.com/san-jose/
 [Seattle] => https://www.survivornet.com/seattle/
 )  [Multiple Myeloma] => Array
 (
 [Ann Arbor] => https://www.survivornet.com/ann-arbor-michigan-multiple-myeloma-treatment/
 [Miami] => https://www.survivornet.com/miami-florida-multiple-myeloma-treatment/
 [Phoenix] => https://www.survivornet.com/phoenix-arizona-multiple-myeloma-treatment/
 )  [Glioma] => Array
 (
 [Midwest] => https://www.survivornet.com/midwest/
 [Mountain States] => https://www.survivornet.com/glioma-mountain-states/
 [Southeast] => https://www.survivornet.com/southeast/
 )  [Prostate Cancer] => Array
 (
 [Houston] => https://www.survivornet.com/houston-advanced-prostate-cancer/
 [Miami] => https://www.survivornet.com/miami-advanced-prostate-cancer/
 [Philadelphia] => https://www.survivornet.com/philadelphia/
 )  [Non-Hodgkin Lymphoma] => Array
 (
 [Houston] => https://www.survivornet.com/houston-advanced-large-b-cell/
 )  )
  Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies Summary  The purpose of this study is to determine if haplotype-mismatched HSCT is associated with an improvement in treatment-related mortality (TRM) rate at 6 months.
 View Eligibility Criteria Eligibility Criteria  Inclusion Criteria:AML , ALL, MDS, CML, Acute myeloid leukemia (AML) with one or more of the following criteria
 Check Your Eligibility 
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1  Location for this study  
 Indiana University Cancer Center  
How clear is this clinincal trial information?
 
    
   Sign Up Sign up now for access to powerful tools, top experts, and customized information to help you fight cancer.
Personalized content tailored to your profile and disease type Access exclusive patient guides Breaking treatment information and expert perspectives and more... Sign Up Now Already have an account? Sign In 
Sign Up Already have an account? Sign In 
Sign In Don't have an account? Sign Up 
Password reset is unavailable because your account was created using 'Sign Up with Google. To continue, please use the Google sign-in button below. Don't have an account? Sign Up